Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 45,400
-1,750 (-3.71%)
At close: Aug 21, 2026
KRX:317450 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 293,031 | 287,254 | 269,435 | 242,338 | 225,828 | 209,250 |
Other Revenue | -0 | -0 | - | - | -0 | -0 |
| 293,031 | 287,254 | 269,435 | 242,338 | 225,828 | 209,250 | |
Revenue Growth | 4.42% | 6.61% | 11.18% | 7.31% | 7.92% | 11.40% |
Cost of Revenue | 112,030 | 113,269 | 100,556 | 88,413 | 82,280 | 70,954 |
Gross Profit | 181,001 | 173,985 | 168,879 | 153,925 | 143,549 | 138,297 |
Selling, General & Admin | 72,114 | 71,553 | 67,800 | 62,249 | 57,227 | 57,643 |
Research & Development | 6,088 | 5,152 | 3,684 | 4,037 | 4,749 | 2,448 |
Amortization of Goodwill & Intangibles | 1.76 | 1.32 | 1.15 | 0.98 | 1.25 | 1.53 |
Other Operating Expenses | 1,755 | 1,683 | 1,588 | 1,485 | 3,564 | 1,326 |
Operating Expenses | 82,695 | 81,487 | 76,124 | 70,306 | 67,646 | 64,091 |
Operating Income | 98,306 | 92,498 | 92,754 | 83,618 | 75,903 | 74,206 |
Interest Expense | -224.13 | -235.34 | -322.65 | -333.54 | -106.64 | -133.33 |
Interest & Investment Income | 12,071 | 9,215 | 8,621 | 6,218 | 2,916 | 835.94 |
Currency Exchange Gain (Loss) | 1,812 | 435.19 | 5,490 | 1,204 | 2,687 | 4,063 |
Other Non Operating Income (Expenses) | 763.42 | 185.13 | -9,548 | 527.79 | 406.58 | 797.02 |
EBT Excluding Unusual Items | 112,730 | 102,099 | 96,994 | 91,235 | 81,806 | 79,768 |
Gain (Loss) on Sale of Investments | - | - | -8,310 | 826.42 | - | - |
Gain (Loss) on Sale of Assets | 20.99 | 20.99 | -609.54 | -0.32 | 10.7 | 6.39 |
Pretax Income | 112,751 | 102,120 | 88,075 | 92,061 | 81,817 | 79,775 |
Income Tax Expense | 23,896 | 20,684 | 19,404 | 17,550 | 24,383 | 20,024 |
Net Income | 88,854 | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 |
Net Income to Common | 88,854 | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 |
Net Income Growth | 14.04% | 18.59% | -7.84% | 29.73% | -3.88% | 31.38% |
Shares Outstanding (Basic) | 14 | 12 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 14 | 12 | 11 | 11 | 11 | 11 |
Shares Change | 23.40% | 8.23% | 0.01% | - | - | - |
EPS (Basic) | 6428.39 | 6717.86 | 6131.00 | 6652.82 | 5128.04 | 5334.82 |
EPS (Diluted) | 6428.39 | 6717.86 | 6131.00 | 6652.82 | 5128.04 | 5334.82 |
EPS Growth | -7.58% | 9.57% | -7.84% | 29.73% | -3.88% | 31.38% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 31,794 | 51,522 | 72,783 | 71,428 | 57,643 | 63,407 |
Free Cash Flow Per Share | 2300.23 | 4250.24 | 6498.19 | 6377.48 | 5146.68 | 5661.37 |
Dividend Per Share | - | - | - | 2000.000 | 1000.000 | 1250.000 |
Dividend Growth | - | - | - | 100.00% | -20.00% | -28.57% |
Gross Margin | 61.77% | 60.57% | 62.68% | 63.52% | 63.57% | 66.09% |
Operating Margin | 33.55% | 32.20% | 34.43% | 34.51% | 33.61% | 35.46% |
Profit Margin | 30.32% | 28.35% | 25.49% | 30.75% | 25.43% | 28.55% |
Free Cash Flow Margin | 10.85% | 17.94% | 27.01% | 29.47% | 25.52% | 30.30% |
EBITDA | 108,467 | 103,439 | 105,217 | 95,058 | 87,238 | 85,824 |
EBITDA Margin | 37.02% | 36.01% | 39.05% | 39.23% | 38.63% | 41.02% |
D&A For EBITDA | 10,160 | 10,940 | 12,463 | 11,440 | 11,336 | 11,619 |
EBIT | 98,306 | 92,498 | 92,754 | 83,618 | 75,903 | 74,206 |
EBIT Margin | 33.55% | 32.20% | 34.43% | 34.51% | 33.61% | 35.46% |
Effective Tax Rate | 21.19% | 20.26% | 22.03% | 19.06% | 29.80% | 25.10% |
Advertising Expenses | - | 28,662 | 31,186 | 27,861 | 25,260 | 27,110 |